Globus MedicalGMED
GMED
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
142% more first-time investments, than exits
New positions opened: 104 | Existing positions closed: 43
110% more call options, than puts
Call options by funds: $24.5M | Put options by funds: $11.7M
16% more capital invested
Capital invested by funds: $7.79B [Q3] → $9.01B (+$1.22B) [Q4]
11% more funds holding
Funds holding: 443 [Q3] → 493 (+50) [Q4]
6% more funds holding in top 10
Funds holding in top 10: 18 [Q3] → 19 (+1) [Q4]
10% more repeat investments, than reductions
Existing positions increased: 166 | Existing positions reduced: 151
0.67% less ownership
Funds ownership: 96.38% [Q3] → 95.7% (-0.67%) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$82
12%
upside
Avg. target
$95
29%
upside
High target
$103
40%
upside
6 analyst ratings
4 positive
67%
2 neutral
33%
0 negative
0%
Truist Securities Richard Newitter 51% 1-year accuracy 22 / 43 met price target | 12%upside $82 | Hold Maintained | 18 Mar 2025 |
Barclays Matt Miksic 59% 1-year accuracy 24 / 41 met price target | 40%upside $103 | Overweight Maintained | 24 Feb 2025 |
Stifel Mathew Blackman 24% 1-year accuracy 4 / 17 met price target | 28%upside $94 | Buy Maintained | 21 Feb 2025 |
Wells Fargo Vik Chopra 36% 1-year accuracy 4 / 11 met price target | 27%upside $93 | Overweight Maintained | 21 Feb 2025 |
Canaccord Genuity William Plovanic 46% 1-year accuracy 22 / 48 met price target | 38%upside $101 | Buy Maintained | 10 Jan 2025 |
Financial journalist opinion
Based on 10 articles about GMED published over the past 30 days
Neutral
Business Wire
1 week ago
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.

Positive
Zacks Investment Research
1 week ago
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.

Positive
Zacks Investment Research
1 week ago
Should You Hold Globus Medical Stock in Your Portfolio Now?
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.

Positive
Zacks Investment Research
2 weeks ago
New Product Launches Benefit GMED Stock Amid Macro Issues
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Positive
Zacks Investment Research
2 weeks ago
Globus Medical Expands Anterior Spine Portfolio With Two New Offerings
GMED announces the commercial launch of COHERE ALIF Spacer and Modulus ALIF Blades.

Neutral
GlobeNewsWire
3 weeks ago
Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades
AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, and Modulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system.

Neutral
GlobeNewsWire
3 weeks ago
Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting
AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, Calif., from March 10-14, 2025.

Neutral
GlobeNewsWire
3 weeks ago
Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference
AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego.

Neutral
Zacks Investment Research
3 weeks ago
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?
Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.

Neutral
PRNewsWire
3 weeks ago
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
REDWOOD CITY, Calif. , March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results.

Charts implemented using Lightweight Charts™